The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 31, 2020

Filed:

May. 07, 2018
Applicants:

The Trustees of the University of Pennsylvania, Philadelphia, PA (US);

The Children's Hospital of Philadelphia, Philadelphia, PA (US);

Inventors:

Carl H. June, Merion Station, PA (US);

Bruce L. Levine, Cherry Hill, NJ (US);

Michael D. Kalos, Philadelphia, PA (US);

Stephan Grupp, Havertown, PA (US);

Assignees:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A01N 65/00 (2009.01); A01N 63/00 (2020.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 35/00 (2006.01); A61K 31/7088 (2006.01); A61K 31/713 (2006.01); A61K 48/00 (2006.01); C12Q 1/6886 (2018.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 31/7088 (2013.01); A61K 31/713 (2013.01); A61K 35/00 (2013.01); A61K 45/06 (2013.01); A61K 48/0083 (2013.01); C12Q 1/6886 (2013.01); G01N 33/6803 (2013.01); A61K 2039/505 (2013.01); A61K 2039/515 (2013.01); G01N 2333/52 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CAR T cell in the patient.


Find Patent Forward Citations

Loading…